Beranda › Kanker Paru Non-Sel Kecil › South Carolina

Uji klinis Kanker Paru Non-Sel Kecil di South Carolina

30 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi di South Carolina.

Kota di South Carolina

Teks studi resmi (Bahasa Inggris)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Medical University of South Carolina /ID# 273272, Charleston
Saint Francis Cancer Center - Greenville /ID# 276368, Greenville

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06568939

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Saint Joseph's/Candler - Bluffton Campus, Bluffton
Prisma Health Cancer Institute - Spartanburg, Boiling Springs
Bon Secours Saint Francis Hospital, Charleston
dan 15 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04267848

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Bon Secours Hematology and Oncology, Greenville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06472245

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #9, Myrtle Beach

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Prisma Health Cancer Institute - Spartanburg, Boiling Springs
Prisma Health Cancer Institute - Easley, Easley
Gibbs Cancer Center-Gaffney, Gaffney
dan 9 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Saint Joseph's Candler Health System ( Site 4010), Bluffton
Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312137

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Medical University of South Carolina, Florence
Medical University of South Carolina Health Lancaster Medical Center, Lancaster

Menerima pesertaFase 3

Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Medical University of South Carolina, Charleston

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Medical University of South Carolina, Charleston
Lexington Medical Center, West Columbia

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06890598

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Greenville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06357533

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

St Francis Cancer Center, Greenville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

PRISMA Health/ITOR, Greenville

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Greenville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06767514

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Carolina Urologic Research Center, Myrtle Beach

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Spartanburg Regional, Spartanburg

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06303505

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

MUSC Hollings Cancer Center, Charleston

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06750185

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Medical University of South Carolina, Charleston
Prisma Health Cancer Institute, Greenville
Lexington Medical Center, West Columbia

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Greenville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07291037

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Medical University of South Carolina, Charleston

Menerima pesertaFase 3

Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT06745908

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson
Saint Joseph's/Candler - Bluffton Campus, Bluffton
Prisma Health Cancer Institute - Spartanburg, Boiling Springs
dan 9 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA03-0, Charleston

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT06953089

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Ralph H Johnson VA Medical Center, Charleston

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson
Saint Joseph's/Candler - Bluffton Campus, Bluffton
Medical University of South Carolina, Charleston
dan 5 lainnya

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson

Menerima pesertaFase 2

18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

Phase 2 Study of Fingolimod in Lung Cancers

Hollings Cancer Center at Medical University of South Carolina, Charleston

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Mar 2026 · NCT06424067

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

AnMed Health Cancer Center, Anderson
Beaufort Memorial Hospital, Beaufort
Saint Joseph's/Candler - Bluffton Campus, Bluffton
dan 18 lainnya

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

The Medical University of South Carolina, Charleston

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT05236114

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Investigational Site, Greenville

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jan 2026 · NCT06999187

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 123, Charleston
Research Site 108, Greenville

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Nov 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Greenville

Menerima pesertaStudi observasional

Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.